Allergy

Blepharitis

COVID-19

Cataract

Comanagement

Comprehensive Eye Exams

Conjunctivitis

Contact Lenses

Cornea

Diabetic Eye Disease

Dry Eye

Geographic Atrophy

Glasses

Glaucoma

LASIK

Lens Technology

Lid and Lash

Myopia

Nutrition

Ocular Surface Disease

Optic Relief

Patient Care

Pediatrics

Presbyopia

Ptosis

Refractive Surgery

Retina

Technology

Therapeutic Cataract & Refractive

News

All News

Practice Management

Media

All Videos

Expert Interviews

Podcasts

Medical World News

Viewpoints

Insights

Case Based Roundtable Series

Case Studies

Case of the Quarter

Practice Ownership

Rapid Readout

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Conference Recaps

Blog

Publications

Digital Edition

Supplements And Featured Publications

iTech

Partners

Resources

Job Board

Subscribe

Videos

Lindsell discusses promising retinal therapeutics, such as at-home therapies, gene therapy, and devices like the Valeda light delivery system (LumiThera), which uses photobiomodulation and shows early promise in preventing geographic atrophy altogether.

CIME 2025: Luke Lindsell, OD, MD, on bridging innovation and practical care in retinal disease

Articles

Topline results from the Magnify phase 2 clinical trial of oral zervimesine show 28.6% slower geographic atrophy lesion growth compared with placebo.

Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics

Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.

Boehringer Ingelheim kicks off dual phase 2 clinical studies for geographic atrophy candidates

The LuxLife full range of vision intraocular lens is available in a range of cylinders spanning from +0.75D to +6.00D.

Bausch + Lomb's LuxLife IOL receives CE Mark approval in Europe

The leading source of breaking news, news analysis, and emerging research reports in optometry, Optometry Times® disseminates practical content by optometrists for optometrists that can be immediately applied to improve the clinical experience.

Advertise

About Us

Editorial

Contact Us

Terms & Conditions

Privacy

Do not sell my Information

Optometry Times | Clinical News & Expert Optometrist Insights

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Myopia- Management

1rem

Authors

What to know about legislative moves that have been made through May this year.

A roundup of legislative news from 2025 so far

Optometric associations, optometrists, and legislators have hit the ground running in 2025 with a flurry of legislative action. With initiatives including pay reforms, addressing vision plan abuses, and simplifying prescription verification systems, legal advocacy has already taken many forms. 

Senator Elizabeth Dole 21st Century Veterans Healthcare and Benefits Improvement Act

A bill signed into law in January provides physician recognition for Department of Veterans Affairs (VA) optometrists, which grants leverage to the department to increase pay awards, bonuses, and annual evaluations to VA eye care providers. With the American Optometric Association (AOA) acting as a longtime advocate for the bill, AOA President Steven Reed, OD, said the passage of the law is a critical win for all optometrists.

"This is huge, not only for the VA ODs, but for all of us," Reed said. "First of all, within the VA system, back in 2004 is when a new law was created that put physicians, the MDs and DOs, in a different pay scale. At that time, the dentists, podiatrists, and optometrists were left off. Over time, though, the dentists and podiatrists were able to be included. But even now, 20 years later, until recently, optometrists were left off. So what that did in the VA system is create some gaps because optometrists don't necessarily have a big motivation to practice in a system where they can't get paid at least comparable to what they could get in the general public. So there are a lot of holes in the system. And then to cap that off, you've got 20% of the VA optometrists at or nearing retirement, so we're about to have a big problem, because VA optometry takes care of the majority of the eye care within that system. 

"So we're very proud for them, and it's a huge win. It's very significant. But I mentioned that it's good for us too, and the reason why is that many times when we're fighting these scope battles or these 'not-a-doctor' bills, which are so prevalent, our opposition will say, 'Well, at the VA level, you guys aren't even recognized as physicians, not to mention that we are at Medicare.' They use that against us, but they can't anymore. So we just took away some of the ammunition."

VA ODs provide approximately 70% of essential primary and medical eye care services. Despite the important role optometry plays in VA health care, ODs had been on the general schedule pay scale, which was largely unchanged since 1976.

Vision/eye health care is the third-most requested service by veterans.

It is estimated that there are approximately 130,000 veterans in the United States who are legally blind and more than 1 million veterans who have low vision that causes a loss of ability to perform necessary daily activities.

As many as 64% of patients with traumatic brain injuries are estimated also to have a vision problem.

A month later, HB 3211 was introduced in Texas to address anticompetitive practices in the vision benefits market. The bill is a continuation of efforts that can be traced to June 2023, when HB 1696 was signed into law. The bill works to prevent abuses, including patient steering, doctor tiering, practice control, chargebacks, and covered services, requiring unrelated information on claims, and extrapolation in audits. 

"HB 3211 strengthens patient choice by ensuring that any properly credentialed optometrist who agrees to the [vision benefits manager's] contract terms can participate as an in-network provider—allowing Texans to see the optometrist of their choice when using their vision plan," Tommy Lucas, OD, director of advocacy at the Texas Optometric Association, said in a news release.

Other recent VBM news comes from Arkansas, with Act 142 of 2025 being signed into law in late February. Members of the Arkansas Optometric Association (ArOA) recently sat down with 

"Everything we do in optometry is legislative, and if we're to advocate for ourselves or our patients, it has to be legislative, and we're going to be the only ones that's going to do that," said Matt Jones, OD, legislative cochair at the ArOA. "So not only was the Arkansas Optometric Association behind this bill—we did this for all eye care providers across the state—but as an affiliate of the American Optometric Association, they were also advocates for this bill. And along with Matt [Burns], Joe [Sugg] and I, we worked with several AOA leaders across the country to help formulate the bill and to help talk through the bill and to make sure that we were on the right path toward advocating for better access for our patients through this VBM bill."

Unfortunately, for as long as I've practiced longer contracts and terms between doctors, these vision plans have become contracts of adhesion, where we have no ability to negotiate," said Joe Sugg, OD, legislative cochair for ArOA. "So they really give a take-it-or-leave-it type of approach, not just in the reimbursement aspect, but many other contractual aspects as well. Obviously, reimbursement is a big, big piece...if doctors don't feel that they can run their practices and get reimbursed appropriately to make a plan make sense, then, unfortunately, they're not going to accept those plans. But now, inherently in optometry, we tend to do it anyway for the good of our patients, whether it makes sense from a business standpoint or not, but not only reimbursement, but just other contractual aspects that we just continue to get squeezed. You try to negotiate these things and just have really no leg to stand on, which is ultimately why we felt something had to be done here to help our patients, ultimately, but also help doctors across the state. This bill also brings more authority for the Department of Insurance to regulate VBMs."

"Previously, it was a little limited, and this brings it under a health benefit plan, or changes that definition so it gives them the ability to regulate these companies, whereas beforehand, that was not the case," said Matt Burns, executive director of ArOA. "So for our doctors, we're going to be implementing education resources from the association to help them with this transition, to make sure that these companies are following the law in conjunction with the Department of Insurance."

The regulations will take effect in August 2025, with additional provisions to roll out based on plan renewals or contract changes or by January 1, 2026.

Most recently, North Dakota secured comprehensive telemedicine provisions as part of its scope of practice legislation. 

"Our members' willingness to step up when called upon was truly incredible and we saw the passion our membership has for their profession," Kim Hacker, North Dakota Optometric Association's executive director, said in a release. "We built lasting relationships at the capitol and walked away with a positive reputation, and as many of you know, that's half the battle."

Biopharmaceutical company Innovent Biologics has completed the first patient dosing in its phase 2 clinical trial assessing efdamrofusp alfa for the treatment of diabetic macular edema (DME).

 The recombinant human VEGFR antibody human complement receptor 1 (CR1) fusion protein was intravitreally administered in DME patients in the randomized, double-masked, multicenter, active-controlled trial (NCT06908876), which assessed the therapy’s efficacy and safety, according to a news release.

The primary end point of the trial is the change in best corrected visual acuity (BCVA) from baseline in the study eye at week 16.

"DME is one of the most common ocular fundus diseases in China, affecting up to 4-5 million patients,” Xiaodong Sun, MD, PhD, the leading principal investigator of the study, deputy director of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, and director of the Ophthalmology Center, stated in the release. “With increasingly the aging of the population and the continuous rise in diabetes prevalence in China, DME has become one of the diseases that seriously endangers public health, imposing heavy burdens to the society and individuals. Anti-VEGF drugs are currently the first-line treatment for DME, but huge unmet medical needs remain, such as frequent injections, long-term efficacy attenuation, and suboptimal response in a subset of patients. As a global first-in-class anti-VEGF-complement bispecific drug, efdamrofusp alfa has shown favorable safety profile, substantial improvement in visual acuity and macular edema, and the potential of extended dosing interval in the completed phase 1 clinical study in DME patients, which has brought great confidence to our investigator team. We look forward to the success of this phase 2 study, hoping to provide of a new treatment option for a large number of DME patients."

A total of 150 patients are planned to be enrolled in the study and randomized 1:1:1 to the IBI302 4-mg group, IBI302 8-mg group, and a farcimad (anti-VEGF/ANG-2 bispecific antibody) 6-mg group.

Edfamrofusp alfa has previously been assessed in multiple clinical studies in patients with neovascular age-related macular degeneration and DME. These studies demonstrated significant efficacy in improving visual acuity and retinal edema in high-dose (8 mg) efdamrofusp alfa. The therapy has also shown the potential for extended dosing intervals up to 12 to 16 weeks with favorable safety and tolerability.

Edfamrofusp alfa works through dual mechanism in the N-terminal as the VEGF-binding domain, and the C-terminal as the complement binding domain that binds C3b and C4b. This allows for inflammatory responses to be alleviated by complement activation. Thus, the dual mechanism is demonstrated in its therapeutic effects of inhibiting VEGF-mediated angiogenesis and complement activation pathways.

Complement system activation is known to contribute to disease progression by damaging neurovascular units via cytolysis, opsonization, and promotion of proinflammatory microenvironment. Retinal microvascular lesions, neurodegeneration, macular edema, and retinal neovascularization are the result.

"Efdamrofusp alfa is an anti-VEGF-complement bispecific fusion protein self-developed by Innovent with global proprietary rights,” Lei Qian, PhD, senior vice president of Clinical Development of Innovent, said in the release. “This clinical study will be globally the first study comparing two dual-target agents, using faricimab, the global standard of care in DME. We look forward to the success of this study, which could provide support for a phase 3 clinical trial and a new treatment option for patients. Innovent's general biomedicine pipeline covers cardiovascular, endocrine and metabolic, ophthalmology, and autoimmune disease areas. We will continue to develop new therapies, providing physicians with more clinical treatment options and benefiting more patients."

Bispecific vs bispecific: Innovent announces first patient dosed in the phase 2 clinical study of efdamrofusp alfa (IBI302), a first-in-class anti-VEGF and anti-complement bispecific fusion protein for the treatment of diabetic macular edema. News release. Innovent Biologics. May 6, 2025. Accessed May 7, 2025. 

https://www.prnewswire.com/news-releases/bispecific-vs-bispecific-innovent-announces-first-patient-dosed-in-the-phase-2-clinical-study-of-efdamrofusp-alfa-ibi302-a-first-in-class-anti-vegf-and-anti-complement-bispecific-fusion-protein-for-the-treatment-of-diabetic-m-302445995.html

The recombinant human VEGFR antibody human complement receptor 1 (CR1) fusion protein will be intravitreally administered in up to 150 patients.

Innovent Biologics completes first patient dosing in its phase 2 clinical trial assessing efdamrofusp alfa in patients with DME 

Phase 2 clinical stage biotechnology company Galimedix Therapeutics has announced the completion of the single ascending dose (SAD) portion of its phase 1 study assessing GAL-101, an oral therapy designed to treat Alzheimer disease, dry age-related macular degeneration (AMD), and glaucoma.

 The small molecule is specifically designed to target misfolded amyloid beta (Aβ) monomers, according to a news release.

The next arm of the study, which includes multiple ascending dose, is   underway and is expected to be completed in late 2025.

“The successful completion of the single ascending dose part of our Phase 1 trial with oral GAL-101 marks an important step forward in our clinical development,” Hermann Russ, MD, PhD, cofounder and chief scientific officer of Galimedix, said in the release. “The data we have seen so far support the safety, tolerability and pharmacokinetic profile we anticipated and reinforce the potential of GAL-101 as an oral therapy for CNS [central nervous system], eye and other diseases associated with amyloid beta pathology, including Alzheimer’s disease. We are proceeding according to plan and are now moving confidently into the next parts of the study, which we are on track to complete later this year.”

In the SAD section of the study, 40 healthy patients were randomly assigned 3:1 to receive either GAL-101 or placebo capsules. GAL-101 was shown to be well tolerated with a highly favorable safety profile, while also demonstrating “an excellent pharmacokinetic profile, strongly supporting the planned oral administration route,” the release said.

The phase 1 trial is ultimately designed to enroll up to 120 patients and is planned to address all relevant aspects required to initiative the planned oral phase 2 studies in Galimedix’s key indications—Alzheimer disease, dry AMD, and glaucoma.

 While the phase 1 trial is ongoing, the company is also conducting a phase 2 eDREAM clinical trial with GAL-101 eye drops for dry AMD. The eDREAM study is expected to complete recruitment in less than a year, according to the release.

In targeting misfolded Aβ monomers, GAL-101 works to prevent the formation of toxic Aβ oligomers and protofibrils. “Many studies have indicated that these Aβ aggregates are a major underlying cause of neurodegenerative diseases of the eye, and recent approvals of anti-Aβ drugs have also validated them as a key target in Alzheimer’s disease,” the release stated. Preclinical testing of GAL-101 demonstrated the compound’s ability to prevent and eliminate all forms of toxic Aβ species while leaving healthy Aβ forms intact. GAL-101 also demonstrated potential for neuroprotection and for symptomatic alleviation of Alzheimer disease in preclinical models of the disease.

A previous phase 1 study assessed GAL-101 in the form of an eye drop and demonstrated excellent safety and tolerability. GAL-101 in its oral form has shown no antibody-specific immunological side effects, such as amyloid-related Imaging abnormalities, low systemic toxicity, strong storage stability, and “easy and inexpensive manufacturing,” the release stated. GAL-101’s efficacy in protecting neuronal retinal cells from toxic damage has otherwise been demonstrated in other relevant ophthalmic preclinical models.

Galimedix Therapeutics completes single ascending dose part of phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator. News release. Galimedix Therapeutics. May 6, 2025. Accessed May 7, 2025. 

https://finance.yahoo.com/news/galimedix-therapeutics-completes-single-ascending-120000532.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAACgUyRp_ORP9y6GDtKFlLbKePeh5zKVSrjSvIw7kcT4Monkji7eUMIRf96oXxcHyQAdLkj2JTjeIxo5cPTiwmesFTrPWy8AuSH76fm0UwY_Q13QqpExryO9cA_HAT1MUnnSRXSD0OY5OM5id43VqIIspgFo-R7BqlO-wgaA_9QfY

The trial assesses GAL-101 as an oral therapy designed to treat Alzheimer disease, dry age-related macular degeneration, and glaucoma.

Galimedix Therapeutics completes single ascending dose portion of phase 1 trial assessing GAL-101

Yi Ni Toh, PhD, and colleagues reported that head-scanning training for patients with hemianopia improved the rates of detection of blind-side hazards, speed of detection of blind-side hazards, and safety during virtual driving. She reported their findings at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting in Salt Lake City, Utah.

The investigators, who are from the Schepens Eye Research Institute of Mass Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, also reported that the benefits of the training, driven by improved blind-side scanning, lasted for more than a month.

“The results demonstrated the potential of our novel training to address deficits in blind-side hazard detection,” they emphasized because of the impairments experienced by patients with hemaniopia.

They explained that homonymous visual field loss (HVFL) impairs blind-side hazard detection due to limited visual field,

 the compensation for which mandates large head scans to the blind side. However, some patients may fail to scan adequately, which increases the risk of collisions.

A previous pilot study reported that real-time auditory reminder cues to scan promoted larger head movements before arriving at intersections and better hazard detection.

A total of 15 patients (median age, 54 years; range, 39-67) participated in this trial. They underwent a preevaluation, 3 training sessions on a driving simulator, and evaluations 1 week and 1 month following their performance on the simulator.

Sixty percent of patients had hemianopia and 40% had quadrantanopia; in 60% of patients, the cause of the HVFL was a stroke.

While using the driving simulator, the participants controlled the speed and steering of the vehicle while driving on city streets. They were tasked with driving with a GPS and honking when they detected a motorcycle. The motorcycles appeared at 38% of intersections on each drive; they approached from the left or right and were visible at an eccentricity between 50 ° and 60 °, Toh recounted.

She reported that the virtual training improved the blind-side hazard detection rate, speed, and safety. Specifically, the training increased blind-side detection compared with baseline (P < .0001); these gains were sustained out to 1 month and approached the participants’ vision level on their sighted side (

The speed with which the participants detected hazards also increased on the blind side (

 < .001). As with detection of hazards, the improvements in speed were sustained at 1 month and were near to those on the sighted side (

The training also improved blind-side detection safety (

 < .0001). The gains were sustained at 1 month and approached the levels on the sighted side (P > .4). The investigators defined safe detection as that occurring with sufficient time to execute a safe maneuver.

The investigators commented, “Training improved the blind-side detection by reducing the scanning errors, ie, failing to scan and not scanning far enough, and increased the scan coverage on the blind side.”

The results conformed to the American Association of Highway and Transportation Officials sight triangle standard, ie, at 40 mph, drivers should be able to see 102 meters (445 feet) down the major road onto which they are turning.

Toh explained that before the participants engaged in training, the blind-side hazards were detected when the scans reached this distance but often missed when they did not. Training increased blind-side scan coverage, calculated by converting the scan magnitude based on the driver’s distance to the intersection at the onset of the scan.

1. Bowers AR, Ananyev E, Mandel AJ, Goldstein RB, Peli E. Driving with hemianopia: IV. Head scanning and detection at intersections in a simulator. 

 2014;55(3):1540–1548. doi:10.1167/iovs.13-12748

2. Swan G, Savage SW, Zhang L, Bowers AR. Driving with hemianopia VII: predicting hazard detection with gaze and head scan magnitude. 

3. Xu J, Emmermann B, Bowers AR. Auditory reminder cues to promote proactive scanning on approach to intersections in drivers with homonymous hemianopia: driving with hemianopia, IX.

 2022;140:75-78. doi:10.1001/jamaophthalmol.2021.5007

Investigators reported that the benefits of the training for patients with hemianopia, driven by improved blind-side scanning, lasted for more than a month.

Conference

ARVO 2025: Head-scanning training program improves blind-side detection during virtual driving for hemianopia patients

supports the finding that myopia control gains with CooperVision’s MiSight 1 day dual-focus soft contact lenses are sustained after treatment, with eye growth aligning with that of untreated, age-matched populations.

 Results from the study indicated that there was no rebound effect with the contact lenses, according to a news release.

Additionally, after treatment cessation, eye growth returned to age-expected levels and the accumulated myopia control treatment gains were retained over the following 12 months after treatment was ceased.

“Eye care professionals (ECPs) have embraced the importance of myopia control in children, and we are starting to see this reflected in prescribing behavior around the world,” said Paul Chamberlain, senior director of research programs at CooperVision and the study’s lead author, in the release. “To turn the tide on childhood myopia, ECPs must be confident in an intervention that not only slows progression but makes long-term treatment worthwhile. MiSight 1 day clearly demonstrates these benefits, allowing ECPs to prescribe with confidence for both immediate and lasting impact.”

The study evaluated participants who completed the 6-year MiSight 1 day clinical trial, including both the cohort who wore the lenses for all 6 years and the cohort who switched from single-vision to the MiSight lenses for the final 3 years, for an additional year following treatment cessation.

The study included 83 participants, with 38 participants with 6 years of prior treatment (referred to as T6) and 40 receiving treatment during study years 4 to 6 (referred to as T3). Axial length and cyclopleged spherical equivalent refractive errors were also monitored annually for 7 years. The study that was conducted in years 1 to 3 (NCT01729208) was a multicenter, double-masked, controlled clinical trial which myopic children aged 8 to 12 years were randomly assigned to wear single-vision control lenses (Proclear 1 day; CooperVision) or MiSight lenses. Participants were then all assigned MiSight lenses in an open-label trial using the same clinical sites in Europe, Southeast Asia, and North America. After completing part 2 of the study, subjects from both cohorts were invited to participate in part 3, a bilateral, open-label trial in year 7 in which all eyes were refit into the Proclear lenses. Visits for part 3 commenced, on average, 2 weeks after the end of part 2. Follow-up visits were scheduled for the 6-month mark and the final visit, which was 1 year after the start of the washout period.

During the untreated year 7, these annual axial growth and refractive changes were reported at 0.09 ± 0.09 (T3) and 0.10 ± 0.10 mm/y (T6), and −0.23 ± 0.36 (T3) and −0.21 ± 0.40 D/y (T6), respectively, with each slightly greater than observed during the previous year of treatment (0.07 ± 0.12 [T3] and 0.08 ± 0.07 mm [T6], and −0.04 ± 0.34 [T3] and −0.13 ± 0.42 D [T6]). Year 7 progression was less for the older (11 to 12 at baseline, −0.17 ± 0.40 D/0.05 ± 0.07 mm) than the younger (8 to 10 at baseline, −0.26 ± 0.36 D/0.13 ± 0.10 mm) subgroup. Years in treatment (3 vs 6) did not influence posttreatment growth or progression.

“The conclusion that post-treatment eye growth and myopia progression was unaffected by the 3 or 6 years of prior treatment centers on the extrapolation of measured untreated growth from the initial control cohort using average growth and progression rates observed in untreated myopic eyes,” the study authors stated. “Conclusions would be better supported if the control group had been retained for 7 years. However, because of the success revealed after the first 3 years of the MiSight 1 day clinical trial, it was considered to be unethical and impractical to retain the control group for additional years of the study.”

Retention of myopia control with MiSight 1 day contact lenses post treatment supported by peer-reviewed journal. News release. CooperVision. May 5, 2025. Accessed May 5, 2025. https://coopervision.com/practitioner/ecp-viewpoints/eyes-coopervision/retention-myopia-control-misight-1-day-contact-lenses#:~:text=The%20results%20indicated%20that%20there,12%20months%20after%20treatment%20ceased.

Chamberlain P, Hammond D, Bradley A, et al. Eye growth and myopia progression following cessation of myopia control therapy with a dual-focus soft contact lens. 

Published online March 25, 2025. doi:10.1097/OPX.0000000000002244

After treatment cessation, eye growth returned to age-expected levels and the accumulated myopia control treatment gains were retained over the following 12 months after treatment was ceased.

New study supports retention of myopia control in CooperVision's MiSight 1 day contact lenses

Aldeyra Therapeutics has achieved primary end point in one of its phase 3 trials of reproxalap for the treatment of 

, which the company will include in the resubmission of the new drug application (NDA) for the therapeutic candidate.

 The dry eye chamber trial was statistically superior to the vehicle in terms of ocular discomfort and while the field trial missed statistical significance for the primary end point, it was consistent with previous field trials and will be submitted with the NDA submission as supportive data. The company intends to resubmit its NDA in mid-2025, pending a Type A meeting with the FDA.

​​“The dry eye chamber results announced today are representative of a number of clinical trials that highlight the potential rapid clinical effect of reproxalap on reducing ocular discomfort,” Todd C. Brady, MD, PhD, president and chief executive officer of Aldeyra, said in a press release. “With no notable baseline differences across treatment arms and highly statistically significant results in favor of reproxalap over vehicle, Aldeyra believes the data potentially address the FDA feedback in the Complete Response Letter received last month and we look forward to meeting with the FDA shortly.”

The phase 3 trial of 0.25% reproxalap was randomized, double masked, and vehicle controlled. In the chamber trial, reproxalap achieved statistical significance for the prespecified end point of ocular discomfort (n = 58) compared with the vehicle (n = 58). The measure was an ocular discomfort symptom score (0-100) from 80 to 100 minutes following chamber entry (LS mean difference [95% CI] -6.5 [-10.5, -2.5]; 

No safety signals or treatment-related discontinuations were reported in either of the recently completed clinical trials. Investigators observed reproxalap to be well tolerated. The most commonly reported adverse event was mild and transient instillation site discomfort, which is consistent with prior clinical trials.

The FDA accepts chamber trial results per its draft guidance for dry eye drug development, but they are rare for dry eye clinical trials. Also called a challenge-model trial, this trial design uses a controlled chamber to regulate temperature, air flow, humidity, and other environmental factors.

 All other dry eye disease therapeutics on the market today have used a more traditional environmental exposure study, marking Aldeyra’s trials as particularly unique.

Because this data contains no notable differences in baseline scores across treatment arms, Aldeyra hopes it will address the concerns listed by the FDA in the 

Complete Response Letter it received in April 2025

most recent NDA submission in November 2024

. At the time, the FDA had found no manufacturing or safety issues with reproxalap, but stated that the submission “failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes” and that “at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye” should be conducted. Additionally, the FDA expressed concerns that the data from the previous chamber trial may have affected interpretation of the results.

“Pending positive results from the ongoing clinical trials and discussions with the FDA, we look forward to a potential NDA resubmission mid-year 2025,” Brady said in a press release at the time of the CRL in April. “Reproxalap remains the only late-stage topical ocular therapy suitable for chronic administration to have potentially demonstrated acute reduction in ocular redness, as well as reduction in ocular discomfort, highlighting rapid and broad activity for both the signs and symptoms of dry eye disease.”

1. Aldeyra Therapeutics achieves primary endpoint in phase 3 dry eye disease chamber trial of Reproxalap and plans NDA resubmission. Aldeyra Therapeutics. Press release. May 5, 2025. Accessed May 6, 2025. 

https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-achieves-primary-endpoint-phase-3-dry-eye-0

2. Harp MD. FDA issues complete response letter to Aldeyra Therapeutics for resubmitted new drug application of reproxalap. 

https://www.optometrytimes.com/view/fda-issues-complete-response-letter-to-aldeyra-therapeutics-for-resubmitted-new-drug-application-of-reproxalap

3. Dry eye: developing drugs for treatment - guidance for industry. FDA. December 14, 2020. Accessed May 6, 2025. 

https://www.fda.gov/media/144594/download

New data for 0.25% reproxalap was announced by Aldeyra Therapeutics, supporting the company’s NDA resubmission for the treatment of dry eye disease.

Luke Lindsell, OD, MD

Articles

Latest Updated Articles